August 2026– date –
-
Aspen Neuroscience’s ANPD001 Cell Therapy for Parkinson’s Disease Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation, Signaling Accelerated Development
RegMedNet USA Overview A RegMedNet report indicates that Aspen Neuroscience's ANPD001 cell therapy for Parkinson's disease has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA, based on preliminary Pha... -
Liv Hospital Accelerates iPSC Therapy with Bioreactor Investment, Targeting Parkinson’s Disease
Liv Hospital Turkey Overview Liv Hospital is addressing the critical challenge of safe and efficient mass production of induced pluripotent stem cells (iPSCs) through a major investment in advanced bioreactor systems. This initiative aim... -
IPS HEART’s iPSC-Derived Cell Therapy ISX9-CPC Receives FDA Rare Pediatric Disease Designation for Muscular Dystrophy-Associated Cardiomyopathy
StreetInsider USA Overview IPS HEART, Inc. announced that its iPSC-derived cell replacement therapy, ISX9-CPC, has received Rare Pediatric Disease Designation (RPDD) from the U.S. FDA for cardiomyopathy associated with muscular dystrophi... -
Porton Advanced Secures China NMPA Commercial Manufacturing License for CGT Products, Expanding CDMO Services from Process Development to Commercialization
Contract Pharma China Overview Porton Advanced has obtained a Class C drug manufacturing license from China's National Medical Products Administration (NMPA), enabling it to provide commercial contract manufacturing services for cell and... -
AI and 3D Bioprinting Transform Regenerative Medicine: Companies like BioLattice Accelerate Organ Manufacturing with Real-Time Quality Control and Optimized Bioinks
Ahead of the Herd Unknown Overview The convergence of artificial intelligence (AI) and 3D bioprinting is accelerating the manufacturing of organs and tissues in regenerative medicine. AI significantly enhances 3D bioprinting accuracy and... -
Resilience and Eli Lilly Expand Strategic Partnership with $750M Investment to Boost U.S. Manufactured Medicine Supply
Resilience USA Overview Resilience and Eli Lilly and Company have expanded their strategic partnership with a significant $750 million investment aimed at increasing the supply of critical medicines manufactured in the U.S. This investme... -
Analysis Group Study: Early CAR-T Therapy Ciltacabtagene Autoleucel Achieves 98.0% Overall Response Rate with Favorable Real-World Outcomes in Relapsed/Refractory Multiple Myeloma
Analysis Group USA Overview An Analysis Group study revealed that early-line CAR-T cell therapy, ciltacabtagene autoleucel (cilta-cel), demonstrated favorable real-world outcomes in relapsed or refractory multiple myeloma (RRMM) patients... -
Catalent Expands AAV Gene Therapy Partnership with Taysha Gene Therapies, Securing Exclusive Commercial Manufacturing for Rett Syndrome Treatment TSHA-102
Pharma Manufacturing USA Overview Taysha Gene Therapies and CDMO Catalent have expanded their strategic partnership, designating Catalent as the exclusive commercial manufacturer for TSHA-102, an AAV-based gene therapy for Rett syndrome,... -
RoosterBio and Applied StemCell Partner to Scale iPSC-Based Bioprocess Solutions, Accelerating Cell Therapy Manufacturing
MD Tech Council (Facebook) USA Overview RoosterBio and Applied StemCell have formed a strategic partnership to scale iPSC-based bioprocess solutions, aiming to accelerate the commercial production of cell therapies. This collaboration in... -
ImmunoAct’s NexCAR19 Achieves 98% MRD Negativity in India with Significant Cost Reduction Compared to Western CAR-T Therapies
Citeline Scrip India Overview ImmunoAct's CAR-T cell therapy, NexCAR19 (talicabtagene autoleucel), achieved a 98% minimal residual disease (MRD) negativity rate in real-world Indian data, delivering comparable efficacy to Western CAR-T t...
